{"id":455314,"date":"2021-03-10T17:02:46","date_gmt":"2021-03-10T22:02:46","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=455314"},"modified":"2021-03-10T17:02:46","modified_gmt":"2021-03-10T22:02:46","slug":"sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/","title":{"rendered":"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SEATTLE, March  10, 2021  (GLOBE NEWSWIRE) &#8212; <strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CltuqKpDxL43oxGi6GCskHyvx4p5CJnzJmKKC5M9mmXSueNlB37J8jBVoqhT98GiGt18qNqKIPexGRUA3-UzhI39DxiroLHMP7SMTDcPcTg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>SEngine Precision Medicine<\/u><\/strong><\/a><\/strong>, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, today announced that data from a study summarizing the predictive value of the PARIS\u00ae Test in ovarian cancer patients will be presented virtually as a poster session (abstract number 534) at the American Association for Cancer Research annual conference, to be held April 10-15, 2021.<\/p>\n<p>Details related to the poster presentation are as follows:<br \/>Title: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilities <br \/>Lead Author:\u00a0Goldie Lui, PhD<br \/>Senior Author: Carla Grandori, MD, PhD<br \/>Abstract Number: 534<br \/>Session Title: Laboratory Correlates for Targeted Agents<\/p>\n<p>Dr. Lui will present clinical and genomic concordance data generated using the PARIS\u00ae Test\u2019s oncology drug sensitivity report. The PARIS\u00ae Test\u2019s reports assessed targeted, endocrine and chemotherapies tested on organoids derived from tumor samples from ovarian cancer patients and identified novel therapeutic vulnerabilities as a useful tool for clinicians\u2019 decision making.<\/p>\n<p>\n        <strong><br \/>\n          <strong>About PARIS\u00ae Test<\/strong>\u00a0<br \/><\/strong>The PARIS\u00ae\u00a0Test is based on the capability to propagate patient-specific cancer\u00a0cells\u00a0as organoids\u00a0outside the body\u00a0and is applicable to all solid tumors\u00a0including colon, breast, lung, ovarian and pancreatic cancer. Organoids are cancer-derived cells grown\u00a0in 3D outside the body, which maintain the functionality of the original tumor as well as its genomic characteristics.\u00a0For cancers\u00a0where\u00a0a treatment\u00a0path is not clear, such as\u00a0many metastatic and recurrent cancers,\u00a0the PARIS\u00ae Test provides crucial information to\u00a0treating physicians\u00a0to\u00a0match the right drug to the right patient.<\/p>\n<p>\n        <strong><br \/>\n          <strong>About SEngine Precision Medicine<\/strong><br \/>\n          <br \/>\n        <\/strong>SEngine Precision Medicine Inc. is a precision oncology company revolutionizing cancer diagnostics and therapies by pre-testing drugs on patient-derived organoids grown ex-vivo utilizing patient specific tumor cells.\u00a0As a spin-out from the world-renowned Fred Hutchinson Cancer Research Center, SEngine is leveraging over two decades of R&amp;D in diagnostics and drug discovery. The Company is commercializing the PARIS\u00ae Test, a next generation diagnostic test that predicts drug responses integrating knowledge of cancer genomics with organoids, robotics, and AI-driven computational tools. SEngine\u2019s CLIA certified PARIS\u00ae Test generates predictive drug sensitivity reports for patients with solid tumors. SEngine is also pursuing drug discovery via strategic collaborations with biopharmaceutical \/ pharma companies leveraging its precision oncology platform.<\/p>\n<p>Discover more at\u00a0<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=t2B955EwsN-x2xg9Oka9HZjKMjOIGaMCm9VGPOqQ_5BP2kzyLDIaZTAfqd0ET1_ihXuEubCKJtfBOB8WO8_rhGo-OJztzt3ezpCguAQk6go=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>SengineMedicine.com<\/u><\/strong><\/a><\/strong>\u00a0and follow the latest news from SEngine on Twitter at\u00a0<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xhi5cmQqNh_0GMaegcXQQc3hTsnVEAg6_FNZ_O8Pkgcd_ZuliiH8bNzd_gR4ac_T7oHqKteQwW0CqpcdeUisdCOiVoc84JCvpwq3iGpAbZ0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>@SEngineMedicine<\/u><\/strong><\/a><\/strong>\u00a0and on\u00a0<strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PqItE6G7eS1QADVDXGNqCtoM84EcqtoP6yXSv4-jKUjDNQOKvNvk4w_V54mH1PMsIz5sVuq7cufT-TaLhIspNl3gUT5xSAPESM6LY_adcMG3Rf5h8luNpeQP1T8C9FdF\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong><u>LinkedIn<\/u><\/strong><\/a><\/strong>.<\/p>\n<p>\n        <strong><br \/>\n          <strong>Contact:<\/strong><br \/>\n          <br \/>\n        <\/strong>Stephanie Carrington<strong><br \/><strong><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ec-eBLIefP7IRH0zc7SZ4Te77C950C4J85HDzLeRIFKbvFZecxorYyHakD5KSJFYCZoTuKrok-2Msk5otRxlrbZ6gfjpjpR5LkiKKEH1yeNbJx0LsFtVzQEYzu82KUw2kvVvo9uKxFuJ7QKMfuur_g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">stephanie.carrington@westwicke.com<br \/><\/a><\/u><\/strong><\/strong>646-277-1282<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/721e1d49-8930-4977-972a-07cbbbb97b2b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEATTLE, March 10, 2021 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, today announced that data from a study summarizing the predictive value of the PARIS\u00ae Test in ovarian cancer patients will be presented virtually as a poster session (abstract number 534) at the American Association for Cancer Research annual conference, to be held April 10-15, 2021. Details related to the poster presentation are as follows:Title: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilities Lead Author:\u00a0Goldie Lui, PhDSenior Author: Carla Grandori, MD, PhDAbstract Number: 534Session Title: Laboratory Correlates for Targeted Agents Dr. Lui will present clinical and genomic &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-455314","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SEATTLE, March 10, 2021 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, today announced that data from a study summarizing the predictive value of the PARIS\u00ae Test in ovarian cancer patients will be presented virtually as a poster session (abstract number 534) at the American Association for Cancer Research annual conference, to be held April 10-15, 2021. Details related to the poster presentation are as follows:Title: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilities Lead Author:\u00a0Goldie Lui, PhDSenior Author: Carla Grandori, MD, PhDAbstract Number: 534Session Title: Laboratory Correlates for Targeted Agents Dr. Lui will present clinical and genomic &hellip; Continue reading &quot;SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-10T22:02:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference\",\"datePublished\":\"2021-03-10T22:02:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/\"},\"wordCount\":426,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/\",\"name\":\"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM=\",\"datePublished\":\"2021-03-10T22:02:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/","og_locale":"en_US","og_type":"article","og_title":"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference - Market Newsdesk","og_description":"SEATTLE, March 10, 2021 (GLOBE NEWSWIRE) &#8212; SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived\u00a0tumor organoids, today announced that data from a study summarizing the predictive value of the PARIS\u00ae Test in ovarian cancer patients will be presented virtually as a poster session (abstract number 534) at the American Association for Cancer Research annual conference, to be held April 10-15, 2021. Details related to the poster presentation are as follows:Title: Functional drug screening of organoids from ovarian cancer patients demonstrates clinical and genomic concordance and identifies novel therapeutic vulnerabilities Lead Author:\u00a0Goldie Lui, PhDSenior Author: Carla Grandori, MD, PhDAbstract Number: 534Session Title: Laboratory Correlates for Targeted Agents Dr. Lui will present clinical and genomic &hellip; Continue reading \"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-10T22:02:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference","datePublished":"2021-03-10T22:02:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/"},"wordCount":426,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/","name":"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM=","datePublished":"2021-03-10T22:02:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODA1MCM0MDU4NTY1IzIxOTc1MjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sengine-precision-medicine-to-present-data-on-predictive-value-of-paris-test-in-ovarian-cancer-patients-at-2021-aacr-annual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SEngine Precision Medicine to Present Data on Predictive Value of PARIS\u00ae Test in Ovarian Cancer Patients at 2021 AACR Annual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/455314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=455314"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/455314\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=455314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=455314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=455314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}